Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabpharm Hong Kong IPO to Raise $172 Million at $900 Million Valuation

publication date: May 21, 2019

Mabpharm, a Taizhou company developing novel drugs and biosimilars for cancers and autoimmune diseases, set the range of its upcoming Hong Kong IPO at between HK$1.50 and HK$1.95 per share. At the midpoint of the range, Mabpharm will raise US$172.2 million at a US$906.4 million valuation. Mabpharm was the 11th pre-revenue biotech to file for a Hong Kong IPO. It is in line to be the ninth to complete the transaction. Mabpharm is developing a portfolio of nine biosimilars, which it hopes will prove to be biobetters. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital